Fig. 5

oHSV pre-treatment followed by CP inhibits clear cell cancer proliferation. A Immune deficient mice (top panel) were injected with OVTOKO cells orthotopically (in the ovarian bursa) and after 6 weeks were either left untreated (OV + PBS), treated with CP (cisplatin), treated with oHSV (oHSV only) or treated oHSV (week 1) followed by CP (week 2–4, oHSV+CP) treatments were delivered via intraperitoneal injection. Decrease in tumor volume is observed following treatment (*p ≤ 0.05 versus untreated controls.) 6 mice were allocated to each group. Large tumor masses were seen in the ovary and kidney in the untreated mice. For the bottom panel, ID8 cells mixed with mouse derived ascites were injected into the ovaries of immunocompetent mice and the treatment groups were same as for the immune deficient mice. B The differences in tumor weight (n = 5, *p0.01) and (C) ascites volume for 6 immune deficient mice in each group. D Western blot of lysates from mice tumor tissues or normal tissues obtained from various groups of treatments. The blot was probed for TMEM205, cleaved PARP, cleaved caspase 3, cleaved caspase 9, and GAPDH. M1 and M2 are different mice from the same group. E Tumor-bearing ovaries were excised, and the consecutive tissue sections were stained for rabbit anti-TMEM205 protein Ab to indicate the distribution of TMEM205. High TMEM205 and Ki67 expression is observed in the untreated group and the group treated with CP alone